Omalizumab chronic spontaneous urticaria
| Autor: | Giorgio Walter Canonica, Eustachio Nettis, Fabio Lodi Rizzini, Luca Cegolon, Elisabetta Di Leo, Aikaterini Detoraki |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty biology business.industry Immunology Treatment outcome Retrospective cohort study Skin test Omalizumab Immunoglobulin E 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine 030228 respiratory system Refractory Internal medicine biology.protein Immunology and Allergy Medicine Observational study In patient business medicine.drug |
| Zdroj: | Annals of Allergy, Asthma & Immunology. 121:474-478 |
| ISSN: | 1081-1206 |
| DOI: | 10.1016/j.anai.2018.06.014 |
| Popis: | Background Omalizumab is a recombinant anti-immunoglobulin E (IgE) antibody used in the treatment of patients with chronic spontaneous urticaria (CSU). Objective This multicentric study assessed the safety and efficacy of omalizumab in patients (n=322) with CSU refractory to second-generation antihistamines, also investigating predictors of poor treatment outcome and time lag to response to anti-IgE therapy by serum auto-reactivity. Methods This retrospective observational study comprised a 4-week pretreatment period, a 24-week treatment period with omalizumab (300 mg/month), and a 16-week follow-up period. Primary efficacy endpoints were mean and median change in 7-day urticaria activity score (UAS7), weekly itch severity score (ISS), and hive score from baseline to 4-, 12-, and 24-week values. Secondary endpoints included the proportion of patients (defined “responders”) with well-controlled urticaria (UAS7 ≤ 6) and complete treatment response (UAS7=0). Safety in terms of side effects was also assessed. Results Omalizumab significantly and consistently reduced the mean UAS7, ISS, and hive score from baseline to weeks 4, 12, and 24, with a clear decreasing trend over time. At the end of the treatment period (week 24), 84.2% of patients had a UAS7 score of 6 or less and 66.7% had a UAS7 of 0. Higher pretreatment IgE levels were less likely to be associated with poor treatment response (ie, UAS7 > 6). Patients with a positive autologus serum skin test (ASST) were significantly more likely to be “slow responders” to omalizumab treatment (ie, response beyond 8 days since omalizumab administration) than ASST-negative patients (P Conclusion Monitoring baseline characteristics of patients before introduction of omalizumab therapy may help to predict treatment outcome in CSU patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|